Coya Therapeutics Inc
COYA
NASDAQ
Biotechnology
$4.79
USD
+0.12 (+2.57%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $109.55M
Volume 113.6K
Revenue
$8.02M
TTM
+1793.8%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-21.67M
TTM
-6.5%
YoY
Operating Cash Flow
$-15.72M
TTM
+4.6%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.2 | 3.6 | 4.0 | 0.3 | 0.2 |
YoY Growth | -95.2% | — | +202768.8% | -2.6% | +49.0% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.2 | 3.6 | 4.0 | 0.3 | 0.2 |
Selling, General & Administrative | 2.9 | 2.6 | 3.3 | 3.8 | 2.3 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 6.6 | 6.0 | 10.0 | 7.9 | 7.3 |
Operating Income | -6.4 | -2.4 | -6.0 | -7.6 | -7.0 |
EBITDA | -6.4 | -2.4 | -6.0 | -7.6 | -7.0 |
Other Income / Expense | 0.3 | 0.3 | 0.3 | 0.4 | 0.4 |
Total Other Income / Expense | 0.3 | 0.3 | 0.3 | 0.4 | 0.4 |
Income Before Income Taxes | -6.1 | -2.1 | -5.7 | -7.2 | -6.6 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -6.1 | -2.1 | -5.7 | -7.2 | -6.6 |
Consolidated Net Income / Loss | -6.1 | -2.1 | -5.7 | -7.2 | -6.6 |
Net Income Attributable to Common Shareholders | -6.1 | -2.1 | -5.7 | -7.2 | -6.6 |
Basic EPS | -$0.36 | -$0.13 | -$0.34 | -$0.32 | -$0.28 |
Diluted EPS | -$0.36 | -$0.13 | -$0.34 | -$0.32 | -$0.28 |
Basic Shares Outstanding | 16.7M | 16.7M | 16.7M | 22.6M | 23.5M |
Diluted Shares Outstanding | 16.7M | 16.7M | 16.7M | 22.6M | 23.5M |